Gourt > Health > Pharmacy > Drugs and Medications > A > Adefovir
Adefovir dipivoxil, previously called bis-POM PMEA, with trade names Preveon® and Hepsera®, is an orally-administered nucleotide analog reverse transcriptase inhibitor (ntRTI) used for treatment of Hepatitis B. It is a failed treatment for HIV.
History
Adefovir was invented in Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic by Antonin Holy, and the drug was developed by Gilead Sciences for HIV with the brand name Preveon. However, in November 1999, an expert panel advised the U.S. Food and Drug Administration (FDA) not to approve the drug due to concerns about the severity and frequency of kidney toxicity when dosed at 60 or 120mg. The FDA followed that advice, refusing to approve adefovir as a treatment for HIV.
Gilead Sciences discontinued its development for HIV treatment in December 1999 but continued to develop the drug for Hepatitis B (HBV), where it is effective with a much lower dose. FDA approval for use in the treatment of Hepatitis B was granted on September 20, 2002, and adefovir is sold for this indication under the brand name Hepsera.
More on [ Adefovir ]
Adefovir - HIVDent - Brief summary of this antiretroviral, nucleotide analog used for the treatment of HIV and AIDS.
Hepsera - Discusses the antiviral drug Hepsera (adefovir dipivoxil), from Gilead Sciences.
Meta Description: [ Information on Hepsera, a Hepatitis B treatment ]
Hepsera Consumer Information - FDA - Patient FAQ in html format with a link to approved labeling in pdf format.
